Side-by-side · Research reference
GHRP-2vsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed15/42 cited
BAnimal-StrongDraft13/39 cited
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
GHRP-2
KPV
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Yes, with somatostatin feedback active
No melanocortin receptor binding
Origin
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-2
KPV
Frequency
1–3× per day
Daily or 2–3× per week
Lower / starter dose
50 mcg per dose
100 mcg / day
Evidence basis
Phase 2 + clinical diagnostic useBowers 1990
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
8–12 weeks on / 4 off (anecdotal)
4–8 weeks per cycle
Reconstitution
Bacteriostatic water
Bacteriostatic water (SQ form)
Timing
Pre-sleep + fasted preferred
No specific time; often taken with / before meals (oral)
04Side Effects & Safety
Parameter
GHRP-2
KPV
Prolactin elevation
Mild but measurable
—
Hunger
Strong appetite increase
—
Injection site reaction
Mild erythema
Mild irritation
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Avoid — insufficient data
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Absolute Contraindications
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
GHRP-2
- ·Untreated diabetes
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
GHRP-2
KPV
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Pre-sleep + fasted preferred.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G insulin syringe (SQ form).
06Stack Synergy
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions